AIMS/HYPOTHESIS: Low levels of IGF-I are associated with increased risk of cardiovascular disease and type 2 diabetes. The aim of this study was to investigate the IGF-I system in patients with acute myocardial infarction (AMI) without previously known diabetes. MATERIALS AND METHODS: One hundred and sixty-eight AMI patients were classified before hospital discharge by means of an OGTT as having NGT, IGT or newly detected type 2 diabetes. Age- and sex-matched subjects from the background population (n=185) served as the control group. The associations between fasting levels of IGF-I and IGF binding proteins 1 and 3 (IGFBP-1, IGFBP-3) and glucose metabolism during a follow-up period of 12 months were studied. RESULTS: At hospital discharge, age-adjusted IGF-I (IGF-I SD) was significantly lower in patients with abnormal glucose tolerance (AGT=IGT or type 2 diabetes) compared with patients with NGT (p=0.014) and control subjects (p<0.001). IGF-I was strongly correlated with IGFBP-3 (r=0.730, p<0.001), which was significantly lower in patients with AGT compared with patients with NGT (p=0.009) and control subjects (p<0.001). Fasting levels of IGFBP-1 did not differ significantly between patients with NGT and AGT or between patients and control subjects. In a multiple logistic regression analysis in patients, IGF-I at hospital discharge was a significant predictor of AGT at discharge and after 12 months (adjusted odds ratio 0.29, p=0.022, and adjusted odds ratio 0.29, p=0.034, respectively). CONCLUSIONS/ INTERPRETATION: Low levels of IGF-I may be a useful predictor of abnormal glucose metabolism in patients with AMI.
AIMS/HYPOTHESIS: Low levels of IGF-I are associated with increased risk of cardiovascular disease and type 2 diabetes. The aim of this study was to investigate the IGF-I system in patients with acute myocardial infarction (AMI) without previously known diabetes. MATERIALS AND METHODS: One hundred and sixty-eight AMI patients were classified before hospital discharge by means of an OGTT as having NGT, IGT or newly detected type 2 diabetes. Age- and sex-matched subjects from the background population (n=185) served as the control group. The associations between fasting levels of IGF-I and IGF binding proteins 1 and 3 (IGFBP-1, IGFBP-3) and glucose metabolism during a follow-up period of 12 months were studied. RESULTS: At hospital discharge, age-adjusted IGF-I (IGF-ISD) was significantly lower in patients with abnormal glucose tolerance (AGT=IGT or type 2 diabetes) compared with patients with NGT (p=0.014) and control subjects (p<0.001). IGF-I was strongly correlated with IGFBP-3 (r=0.730, p<0.001), which was significantly lower in patients with AGT compared with patients with NGT (p=0.009) and control subjects (p<0.001). Fasting levels of IGFBP-1 did not differ significantly between patients with NGT and AGT or between patients and control subjects. In a multiple logistic regression analysis in patients, IGF-I at hospital discharge was a significant predictor of AGT at discharge and after 12 months (adjusted odds ratio 0.29, p=0.022, and adjusted odds ratio 0.29, p=0.034, respectively). CONCLUSIONS/ INTERPRETATION: Low levels of IGF-I may be a useful predictor of abnormal glucose metabolism in patients with AMI.
Authors: N Vaessen; P Heutink; J A Janssen; J C Witteman; L Testers; A Hofman; S W Lamberts; B A Oostra; H A Pols; C M van Duijn Journal: Diabetes Date: 2001-03 Impact factor: 9.461
Authors: Manjinder S Sandhu; Adrian H Heald; J Martin Gibson; J Kennedy Cruickshank; David B Dunger; Nicholas J Wareham Journal: Lancet Date: 2002-05-18 Impact factor: 79.321
Authors: Adrian H Heald; K W Siddals; William Fraser; William Taylor; Kalpana Kaushal; Julie Morris; Robert J Young; Anne White; J Martin Gibson Journal: Diabetes Date: 2002-08 Impact factor: 9.461
Authors: P Spallarossa; C Brunelli; F Minuto; D Caruso; M Battistini; S Caponnetto; R Cordera Journal: Am J Cardiol Date: 1996-01-15 Impact factor: 2.778
Authors: Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler Journal: Diabetes Metab Res Rev Date: 2009-01 Impact factor: 4.876
Authors: Peter R van Dijk; Gijs W D Landman; Larissa van Essen; Joachim Struck; Klaas H Groenier; Henk J G Bilo; Stephan J L Bakker; Nanne Kleefstra Journal: BMC Endocr Disord Date: 2015-04-14 Impact factor: 2.763
Authors: Cindya P Iswandi; Victor J van den Berg; Suat Simsek; Daan van Velzen; Edwin Ten Boekel; Jan-Hein Cornel; Sanneke de Boer; Maarten de Mulder; K Martijn Akkerhuis; Eric Boersma; Victor A Umans; Isabella Kardys Journal: Diab Vasc Dis Res Date: 2021 Nov-Dec Impact factor: 3.291
Authors: Figen Aydin; Ahmet Kaya; Levent Karapinar; Mert Kumbaraci; Ahmet Imerci; Hasan Karapinar; Cengiz Karakuzu; Mustafa Incesu Journal: J Diabetes Res Date: 2013-02-26 Impact factor: 4.011